Arthur V. Miller
Bristol-Myers Squibb
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Arthur V. Miller.
Bioorganic & Medicinal Chemistry Letters | 2008
Lalgudi S. Harikrishnan; Muthoni G. Kamau; Timothy Herpin; George C. Morton; Yalei Liu; Christopher B. Cooper; Mark E. Salvati; Jennifer X. Qiao; Tammy C. Wang; Leonard P. Adam; David S. Taylor; Alice Ye A. Chen; Xiaohong Yin; Ramakrishna Seethala; Tara L. Peterson; David S. Nirschl; Arthur V. Miller; Carolyn A. Weigelt; Kingsley K. Appiah; Jonathan O’Connell; R. Michael Lawrence
2-Arylbenzoxazole 5 was identified as a hit from a fluorescence-based high-throughput screen for CETP inhibitors. The synthesis and SAR investigation employing array synthesis of the A- and B-rings are described.
Journal of Medicinal Chemistry | 2012
Lalgudi S. Harikrishnan; Heather Finlay; Jennifer X. Qiao; Muthoni G. Kamau; Ji Jiang; Tammy C. Wang; James C. B. Li; Christopher B. Cooper; Michael A. Poss; Leonard P. Adam; David S. Taylor; Alice Ye A. Chen; Xiaohong Yin; Paul G. Sleph; Richard Yang; Doree Sitkoff; Michael A. Galella; David S. Nirschl; Katy Van Kirk; Arthur V. Miller; Christine Huang; Ming Chang; Xue-Qing Chen; Mark E. Salvati; Ruth R. Wexler; R. Michael Lawrence
A series of diphenylpyridylethanamine (DPPE) derivatives was identified exhibiting potent CETP inhibition. Replacing the labile ester functionality in the initial lead 7 generated a series of amides and ureas. Further optimization of the DPPE series for potency resulted in the discovery of cyclopentylurea 15d, which demonstrated a reduction in cholesterol ester transfer activity (48% of predose level) in hCETP/apoB-100 dual transgenic mice. The PK profile of 15d was suboptimal, and further optimization of the N-terminus resulted in the discovery of amide 20 with an improved PK profile and robust efficacy in transgenic hCETP/apoB-100 mice and in hamsters. Compound 20 demonstrated no significant changes in either mean arterial blood pressure or heart rate in telemeterized rats despite sustained high exposures.
Bioorganic & Medicinal Chemistry Letters | 1992
Harold N. Weller; Arthur V. Miller; Robert V. Moquin; Kenneth E.J. Dickinson; S.Anders Hedberg; Suzanne Moreland; Robert Cohen; Carol L. Delaney; S. Skwish; Sharon Williams
Abstract N-Biphenylmethyl benzothiadiazine dioxides were prepared as potential angiotensin-II receptor antagonists. Stability of the compounds is dependent upon the nature of the substituent at position 3 of the benzothiadiazine ring, while potency is dependent upon the nature of substitution in the benzo fused ring. 3-(Propylthio)-4-[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-ylmethyl]-4H-1,2,4-benzothiadiazine-6-carboxylic acid, 1,1-dioxide ( 17 ) is one of the most potent examples, with functional activity (K B ) below 01 nM.
Bioorganic & Medicinal Chemistry Letters | 2011
Lalgudi S. Harikrishnan; Muthoni G. Kamau; Honghe Wan; Jennifer Inghrim; Kurt Zimmermann; Xiaopeng Sang; Harold Mastalerz; Walter Lewis Johnson; Guifen Zhang; Louis J. Lombardo; Michael A. Poss; George L. Trainor; John S. Tokarski; Matthew V. Lorenzi; Dan You; Marco M. Gottardis; Kathy F. Baldwin; Jonathan Lippy; David S. Nirschl; Ruhui Qiu; Arthur V. Miller; Javed Khan; John S. Sack; Ashok V. Purandare
SAR studies of pyrrolo[1,2-f]triazines as JAK2 inhibitors is presented. Achieving JAK2 inhibition selectively over JAK3 is discussed.
Heterocycles | 1993
Harold N. Weller; Arthur V. Miller; Kenneth E.J. Dickinson; S.Anders Hedberg; Carol L. Delaney; Randolph P. Serafino; Suzanne Moreland
4-Alkyl-1,2,4-oxadiazinones were prepared by regiospecific alkylation of the corresponding 4H-oxadiazinones, which were synthesized by a trimethylaluminium mediated cyclization reaction. Alkylation was regiospecific and generally facile; in one example, however, an unusual fragmentation reaction occurred. A homochiral oxadiazineone was also prepared and alkylated under the described conditions. 4-Biphenylmethyl-1,2,4-oxadi-azinones were potent angiotensin-II receptor antagonists
Tetrahedron Letters | 1996
Charles Z. Ding; Arthur V. Miller
Abstract Various heteroaryls were found to undergo 1,4-oxygen to nitrogen migration (e.g. 4→1 ) under acidic conditions. This unprecedented migratin provides a convenient access to 4-(N-alkyl-N-heteroaryl)amino-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-6-carbonitrile derivatives, which are otherwise difficult to prepare.
Journal of Medicinal Chemistry | 2000
John T. Hunt; Charles Z. Ding; Roberta Batorsky; Mark S. Bednarz; Rajeev S. Bhide; Young H. Cho; Saeho Chong; Sam T. Chao; Johnni Gullo-Brown; Peng Guo; Soong Hoon Kim; Francis Y. Lee; Katerina Leftheris; Arthur V. Miller; Toomas Mitt; Manorama Patel; Becky Penhallow; Carol Ricca; William C. Rose; Robert J. Schmidt; William Allen Slusarchyk; Gregory D. Vite; Veeraswamy Manne
Journal of Medicinal Chemistry | 1993
Kyoung S. Kim; Ligang Qian; J. E. Bird; Kenneth E.J. Dickinson; Suzanne Moreland; Thomas R. Schaeffer; Thomas L. Waldron; Carol L. Delaney; Harold N. Weller; Arthur V. Miller
Journal of Medicinal Chemistry | 1999
Charles Z. Ding; Roberta Batorsky; Rajeev S. Bhide; Chao Hj; Young H. Cho; Chong S; Johnni Gullo-Brown; Peng Guo; Kim Sh; Francis Y. Lee; Katerina Leftheris; Arthur V. Miller; Toomas Mitt; Manorama Patel; Becky Penhallow; Carol Ricca; William C. Rose; Robert J. Schmidt; William Allen Slusarchyk; Gregory D. Vite; Ning Yan; Manne; John T. Hunt
Bioorganic & Medicinal Chemistry Letters | 2004
Lawrence G. Hamann; Charles Z. Ding; Arthur V. Miller; Cort S. Madsen; Paulina Wang; Philip D. Stein; Andrew T. Pudzianowski; David W. Green; Hossain Monshizadegan; Karnail S. Atwal